Investing.com - Merck&Co (NYSE: MRK) reported third quarter EPS of $2.13, $0.18 better than the analyst estimate of $1.95. Revenue for the quarter came in at $16B versus the consensus estimate of $15.29B.
Guidance
Merck&Co sees FY 2023 EPS of $3.03-$3.08 versus the analyst consensus of $2.86.
Merck&Co sees FY 2023 revenue of $59.70B-$60.20B versus the analyst consensus of $55.98B.
Merck&Co's stock price closed at $103.63. It is down -2.55% in the last 3 months and up 3.90% in the last 12 months.
Merck&Co saw 7 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
